E lucidation of the molecular basis for normal and abnormal organ function is being accelerated as a result of the application of the techniques of molecular genetics and linkage analysis. Application of these techniques to cardiac disorders has been sparse until recent investigation of familial hypertrophic cardiomyopathy (FHCM). FHCM, an inherited primary cardiac abnormality characterized by ventricular hypertrophy, is the leading cause of sudden death in the young.1,2 This disorder has undergone exhaustive clinical, hemody-namic, and pathological study that has contributed significantly to our understanding of ventricular function and cardiac failure. Compared with most instances of cardiac hypertrophy, hypertrophy of the cardiac muscle in hypertrophic cardiomyopathy (HCM) appears to be primary rather than secondary to increased workload. It is also characterized by impaired diastolic relaxation, a feature of cardiac failure from other causes.3 This suggests that the underlying genetic defect is fundamental to cardiac growth and sarcomere assembly; thus, FHCM may serve as an excellent paradigm for the study of molecular mechanisms underlying cardiac repair, growth, and hypertrophy. Clinical studies4 confirm autosomal dominant inheritance, but the presence and severity of signs and symptoms vary markedly, tending to increase with age.
The development of DNA markers recognizing restriction fragment length polymorphisms (RFLPs) spanning the human genome has provided the geneticist with a method of mapping the location of genes previously unavailable. Random changes in the DNA sequence, which occur every 100-500 base pairs in the human genome,5 can result in an altered pattern produced on a Southern blot by hybridizing with a cloned probe homologous to adjacent DNA sequences. Each of these patterns is inherited in an autosomal codominant fashion so that the presence or absence of a recognition site (i.e., each allele of the RFLP) can be unambiguously determined, and its inheritance from parent to child can be followed in families. If particular alleles of an RFLP tend to be coinherited with a disease with a more-than-random frequency within a family, the disease is said to be linked to the marker. It is important to note that this does not mean that a particular allele of the RFLP will be associated with the disease in the general population. Genetic In the past year, application of linkage analysis using RFLP markers to determine the locus of the gene for HCM has provided exciting and provocative results. Summarizing recent results, linkage to prealbumin on chromosome 18 has been suggested by Nishi et al. 6 In an Italian study in which more indirect methods were used, the investigators suggested that the gene for HCM was located on chromosome 16.7 In a recent study of one large French-Canadian family, Jarcho et a18 documented linkage in 14ql with a lod score of 9.37, whereas Solomon et a19 documented that other families are not linked to this locus. Investigators at the National Institutes of Health studied a large number of individuals from several families and reported the locus in at least one of these families to be on chromosome 2ql.10 These results suggest genetic heterogeneity. Because of the varied phenotypic expression of the clinical features of this disease, clinicians have for some time expected the disease to be heterogeneous in its etiology and pathogenesis. However, until there is confirmation of at least one of these loci in unrelated pedigrees by independent investigations, definitive interpretation remains speculative. In the present study, we studied eight unrelated families of varied ethnic origins from across the United States with autosomal dominant inheritance of the gene for FHCM. The families under study showed linkage to markers in 14ql with no statistical evidence for genetic heterogeneity, although this possibility could not be excluded. This confirms the linkage of FHCM to chromosome 14ql and suggests that a gene in this region might be a frequent cause of FHCM in the US population.
Methods

Patient Studies
Eight families identified through an affected family member underwent detailed cardiovascular examination and two-dimensional echocardiography. Some family members were deceased, and clinical status was determined by medical records. The echocardiographic criterion for being affected was 
Results
Pedigrees of the families studied are shown in Figure 1 . All individuals marked as affected met the stringent diagnostic criterion detailed in "Methods."
Individuals not examined are marked as unknown, as are individuals who marginally met or missed the diagnostic criterion. In addition, individuals with diseases that might confound the diagnosis or who belonged in age groups that were considered to obscure the diagnosis are also marked as unknown.
Two-point linkage analysis was performed with a variety of protein and blood group markers and with RFLP markers on chromosomes 6, 17, and 19 and gave no evidence for linkage (data not shown). Analysis with probes of the HLA region (pCH6, 21-hydroxylase, HLA-A2, HLA-B7, DRa, DR,B, DQa, DQ(3, and factor 13) excluded linkage to this region. Two-point linkage analysis using markers in the chromosome 14ql region was suggestive of linkage. The resulting summed lod scores ranged from 2.63 with TCRA to 1.34 with D14S26 (Table 2) . Using the age-dependent penetrance curve described in "Methods," D14S25 and D14S26 showed maximum lod scores at recombination frequencies of 0.03 and 0.05, respectively. Under the arbitrary assumption of complete penetrance and no false-positive diagnoses, single obligate recombinants occurred between HCM 
